Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA – Get Free Report) traded down 5.6% during trading on Friday after HC Wainwright lowered their price target on the stock from $45.00 to $30.00. HC Wainwright currently has a buy rating on the stock. Tyra Biosciences traded as low as $22.33 and last traded at $22.21. 913,818 shares changed hands during mid-day trading, an increase of 0% from the average daily volume of 912,001 shares. The stock had previously closed at $23.54.
TYRA has been the topic of several other reports. Piper Sandler restated an “overweight” rating and set a $56.00 target price on shares of Tyra Biosciences in a report on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Tyra Biosciences in a report on Friday, July 17th. JonesTrading initiated coverage on Tyra Biosciences in a research report on Wednesday, June 17th. They set a “buy” rating and a $56.00 target price for the company. Bank of America boosted their price objective on shares of Tyra Biosciences from $37.00 to $42.00 and gave the stock a “buy” rating in a research note on Wednesday, June 10th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $42.00 target price on shares of Tyra Biosciences in a report on Wednesday, August 5th. Eleven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $47.88.
View Our Latest Stock Analysis on TYRA
Key Headlines Impacting Tyra Biosciences
- Positive Sentiment: Wedbush maintained an “outperform” rating and set a $53 price target, implying substantial potential upside from recent trading levels. The firm’s stance suggests it views the selloff as excessive relative to Tyra’s longer-term prospects. Wedbush analyst rating report
- Positive Sentiment: Coverage of the SURF302 results indicated that dabogratinib demonstrated activity in FGFR3-driven bladder cancer, supporting continued development of Tyra’s lead program. The Pharma Letter SURF302 report
- Neutral Sentiment: HC Wainwright retained a “buy” rating but reduced its price target from $45 to $30, reflecting a more cautious outlook while still anticipating upside. HC Wainwright analyst rating report
- Neutral Sentiment: Reported short-interest data showed zero shares sold short, offering no meaningful indication of bearish positioning; the figure may reflect incomplete or unreliable data rather than a substantive trading signal.
- Negative Sentiment: Investors reacted negatively to initial SURF302 results because bladder-cancer response rates were viewed as falling short of expectations. Coverage described the data as disappointing, raising questions about dabogratinib’s competitive positioning and future commercial potential. BioSpace SURF302 coverage
- Negative Sentiment: Pomerantz LLP announced an investigation into potential claims on behalf of Tyra investors. The announcement does not establish wrongdoing, but it adds headline and legal risk at a time when sentiment is already weak. Pomerantz investor alert
Institutional Trading of Tyra Biosciences
Hedge funds have recently bought and sold shares of the stock. Tidal Investments LLC acquired a new position in shares of Tyra Biosciences during the second quarter valued at about $943,000. WINTON GROUP Ltd acquired a new position in Tyra Biosciences in the 2nd quarter valued at approximately $537,000. Engineers Gate Manager LP bought a new stake in shares of Tyra Biosciences in the 2nd quarter worth approximately $1,021,000. Squarepoint Ops LLC lifted its position in shares of Tyra Biosciences by 211.3% in the 2nd quarter. Squarepoint Ops LLC now owns 63,805 shares of the company’s stock worth $2,038,000 after acquiring an additional 43,311 shares during the period. Finally, California State Teachers Retirement System grew its holdings in shares of Tyra Biosciences by 55,815.5% during the 2nd quarter. California State Teachers Retirement System now owns 783,935 shares of the company’s stock worth $24,544,000 after purchasing an additional 782,533 shares in the last quarter. 84.14% of the stock is owned by institutional investors.
Tyra Biosciences Stock Down 6.3%
The business has a 50-day moving average price of $28.56 and a 200-day moving average price of $31.91. The firm has a market capitalization of $1.32 billion, a P/E ratio of -9.19 and a beta of 0.73.
Tyra Biosciences (NASDAQ:TYRA – Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). As a group, sell-side analysts forecast that Tyra Biosciences, Inc. will post -2.74 EPS for the current year.
Tyra Biosciences Company Profile
Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.
The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.
Featured Stories
- Five stocks we like better than Tyra Biosciences
- Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
- Kroger’s Textbook Entry for Buy-and-Hold Investors
- AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
- Amgen Drops 10% on a Trial It Didn’t Even Run
Receive News & Ratings for Tyra Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyra Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
